Last reviewed · How we verify
other causes of cognitive decline
Approved treatments
- Neuraceq · Life Molecular
- Neuraceq · Life Molecular
- Vizamyl · Ge Healthcare
Vizamyl works by binding to amyloid plaques in the brain, allowing for visualization through positron emission tomography (PET) imaging. - Vizamyl · Ge Healthcare
Vizamyl works by binding to amyloid plaques in the brain, allowing for visualization through positron emission tomography (PET) imaging. - Amyvid · Avid Radiopharms Inc
Amyvid binds to beta-amyloid plaques in the brain, allowing for visualization of these plaques through PET imaging. - Amyvid · Avid Radiopharms Inc
Amyvid binds to beta-amyloid plaques in the brain, allowing for visualization of these plaques through PET imaging.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- other causes of cognitive decline patent landscape — cliff calendar, originator estates, attackable patents
- other causes of cognitive decline treatment landscape brief
- other causes of cognitive decline treatment updates RSS
Frequently asked questions about other causes of cognitive decline
What drugs treat other causes of cognitive decline?
Tracked treatments include Neuraceq, Vizamyl, Amyvid.
What is the treatment for other causes of cognitive decline?
Standard treatment for other causes of cognitive decline includes Neuraceq, Vizamyl, Amyvid. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: other causes of cognitive decline patent cliff · other causes of cognitive decline CI report
- Treatment: Neuraceq · Life Molecular
- Treatment: Neuraceq · Life Molecular
- Treatment: Vizamyl · Ge Healthcare
- Treatment: Vizamyl · Ge Healthcare
- Treatment: Amyvid · Avid Radiopharms Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing